Antibody Contract Manufacturing Market Size and Forecast 2024-2033|AbbVie Inc., Thermo Fisher Scientific Inc., Boehringer Ingelheim Biopharmaceuticals GmbH, Fujifilm Holdings Corporation, Eurofins Scientific SE

rider on motorbike

The Antibody Contract Manufacturing Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Antibody Contract Manufacturing Market:

https://www.thebusinessresearchcompany.com/report/antibody-contract-manufacturing-global-market-report

According to The Business Research Company’s Antibody Contract Manufacturing Global Market Report 2024, The antibody contract manufacturing market size has grown rapidly in recent years. It will grow from $12.84 billion in 2023 to $14.71 billion in 2024 at a compound annual growth rate (CAGR) of 14.6%. The growth in the historic period can be attributed to increased demand for monoclonal antibodies, shift towards personalized medicine, cost optimization, stringent regulatory requirements, globalization of biologics.

The antibody contract manufacturing market size is expected to see rapid growth in the next few years. It will grow to $25.27 billion in 2028 at a compound annual growth rate (CAGR) of 14.5%. The growth in the forecast period can be attributed to increasing r&d spending, expansion of bispecific and multispecific antibodies, rise of antibody-drug conjugates (adcs), increasing healthcare infrastructure, growing government initiatives. Major trends in the forecast period include digitalization and data analytics, advanced upstream technologies, novel downstream processing techniques, sustainability initiatives, contract development and manufacturing integration (cdmo).

The rising number of clinical trials is expected to propel the growth of the antibody contract manufacturing market going forward. Clinical trials are research studies conducted with human participants to evaluate the safety and effectiveness of new medical treatments, interventions, or diagnostic procedures. The number of clinical trials involving antibody-based therapeutics or diagnostics expands, for high-quality antibodies, ensuring a timely and compliant supply for clinical trials. For instance, in May 2023, according to ClinicalTrials.gov, a part of the National Institutes of Health (NIH), a US-based government agency responsible for conducting and supporting medical research, in all 50 states of the United States and 221 countries, the number of registered clinical trials studies climbed from 399,499 in 2022 to 437,533 in 2023. Additionally, around 241,498 studies, or 53% of the total, were registered outside the United States, compared to 140,492 studies (31%) registered just in the United States. Therefore, the rising number of clinical trials is driving the growth of the antibody contract manufacturing market.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=12665&type=smp

The antibody contract manufacturing market covered in this report is segmented –

1) By Product: Monoclonal Antibodies, Polyclonal Antibodies, Other Products

2) By Source: Mammalian, Microbial

3) Scale Of Operation: Preclinical, Clinical, Commercial

4) By End-User: Biopharmaceutical Companies, Research Laboratories, Other End Users

Technological advancements are a key trend gaining popularity in the antibody contract manufacturing market. Major companies operating in the antibody contract manufacturing market are adopting new technologies to sustain their position in the market. For instance, in October 2021, Merck KGaA, a Germany-based science and technology company, introduced ChetoSensar, an innovative technology aimed at addressing solubility challenges in antibody-drug conjugates (ADCs). Merck KGaA intends to leverage their expertise in contract development manufacturing for the development of next-generation antibody-drug conjugates and improve the effectiveness of high-potency active pharmaceutical ingredients (HPAPIs) by enhancing the solubility of these compounds through the innovative ChetoSensar technology.

The antibody contract manufacturing market report table of contents includes:

1. Executive Summary

2. Antibody Contract Manufacturing Market Characteristics

3. Antibody Contract Manufacturing Market Trends And Strategies

4. Antibody Contract Manufacturing Market – Macro Economic Scenario

5. Global Antibody Contract Manufacturing Market Size and Growth

26. South America Antibody Contract Manufacturing Market

27. Brazil Antibody Contract Manufacturing Market

28. Middle East Antibody Contract Manufacturing Market

29. Africa Antibody Contract Manufacturing Market

30. Antibody Contract Manufacturing Market Competitive Landscape And Company Profiles

Top Major Players: